Twitter/X

Nan Ransohoff launched Intercept on 2026-06-24

2026-06-24 · 12:43 UTC ·@bswud ·1 min read

Brief

Nan Ransohoff announced Intercept, a $500M philanthropic effort launched 2026-06-24 to eliminate respiratory infections by funding broad‑spectrum preventatives and air‑cleaning tech. She cites ~5% of life spent sick, ~1M deaths/year and $600B lost productivity; a ~40‑expert convening flagged technical complexity and underfunding as the main barriers. The author, a parent, praises the initiative.

Why it matters

Nan Ransohoff launched Intercept on 2026-06-24: a $500M philanthropic initiative to make respiratory infections (e.g., common cold, flu) a thing of the past by catalyzing broad‑spectrum preventatives and air‑cleaning technologies; anchor funders include Stripe, Anthropic, TheFluLab, @FoundationOAI and individuals from Jane Street.

Key details

  • Ransohoff cites that respiratory viruses make people sick ~5% of their lives, kill ~1 million people annually, and cost $600 billion per year in productivity; a convening of ~40 scientists, pharma R&D leaders, biotech investors and regulatory experts last year identified two barriers: (1) technical difficulty from hundreds of mutating strains and (2) chronic underfunding.
  • Author @bswud, a parent with two children in nursery, calls Intercept 'one of the most important projects imaginable' and thanks Nan Ransohoff for launching it.
Source evidence

From the perspective of society this is one of the most important projects imaginable. From the perspective of me, a parent with two children in nursery (daycare) it is selfishly one of the most important projects imaginable. Thank God for Nan Ransohoff!

Nan Ransohoff (@nanransohoff)

Today we're launching Intercept: a $500M philanthropic initiative to make respiratory infections, like the common cold and flu, a thing of the past.

We treat respiratory infections as a minor nuisance, but that’s really not the case. Most of us will spend 5% of our lives (!) sick from these viruses, they kill 1M people a year, cost $600B annually in productivity, and periodically threaten civilization through pandemics.

So, if they’re such a big problem, why haven’t we dealt with them yet? Last year we convened ~40 leading scientists, pharma R&D leaders, biotech investors, and regulatory experts to better understand that.

We heard two main reasons:
(1) First, it’s just technically very challenging: respiratory viruses represent hundreds of distinct, mutating strains across several families. Fortunately, recent breakthroughs make this newly possible.
(2) Second is a lack of funding: broad-spectrum solutions have historically been underfunded, in part because they’re not a great fit for most philanthropic or commercial funding (and while COVID generated a burst of activity around preventing and understanding respiratory infections through an influx of new funding, that hasn't been sustained).

We think that with enough focus and funding, this might be solvable. Intercept is a $500 million philanthropic initiative that will take advantage of new tools to catalyze the development and deployment of two types of products: broad-spectrum preventatives and air cleaning technologies.

This problem is undoubtedly difficult. But it’s more tractable now than it’s ever been. We think we should give it our best shot.

We’re enormously grateful to our anchor funders: @stripe, @AnthropicAI, @TheFluLab, @FoundationOAI and individuals from Jane Street.

And, I’m very excited to be building this with @incredutility and the rest of the team.

— https://nitter.net/nanransohoff/status/2069761661456601188#m